A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 1, 2012, Pages

  Clewes, Jane ^a  

^a Staffordshire   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOFEPRAMINE; PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; EAR INFECTION; FEMALE; HEARING LOSS; HEARING TEST; HUMAN; PANIC; PATIENT ASSESSMENT; RELAPSE; TINNITUS; TREATMENT DURATION;

EID: 84864003869     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11br01218     Document Type: Article

References (65)

1. Berigan TR. Mirtazapine-associated withdrawal symptoms: a case report. Prim Care Companion J Clin Psychiatry. 2001;3(3):143. PubMed doi:10.4088/PCC.v03n0307aShow Abstract
2. Drugs and Therapy Perspectives. Stopping antidepressant therapy may result in transient and usually mild discontinuation symptoms. Drugs Ther Perspect. 2008;24(2):23-24. doi:10.2165/00042310-200824020-00008
3. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183-197. PubMed doi:10.2165/00002018-200124030-00003 Show Abstract
4. Howland RH. Potential adverse effects of discontinuing psychotropic drugs, pt 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010;48(7):9-12. PubMeddoi:10.3928/02793695-20100527-98 Show Abstract
5. Schatzberg AF, Haddad P, Kaplan EM, et al; Discontinuation Consensus Panel. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry. 1997;58(suppl 7):23-27. PubMed Show Abstract
6. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008;22(3):330-332. PubMed doi:10.1177/0269881107081550 Show Abstract
7. Haddad PM, Anderson I, Rosenbaum J. Antidepressant discontinuation syndromes. In: Haddad P, Sursun S, Deakin W, eds. Adverse Syndromes and Psychiatric Drugs: a Clinical Guide. Oxford, England: Oxford Medical Publications; 2004:183-205.
8. Berber MJ. FINISH: remembering the discontinuation syndrome: flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (anxiety/agitation). J Clin Psychiatry. 1998;59(5):255. PubMed doi:10.4088/JCP.v59n0509b Show Abstract
9. Agelink MW, Zitzelsberger A, Klieser E. Withdrawal syndrome after discontinuation of venlafaxine. (letter) Am J Psychiatry. 1997;154(10):1473-1474. PubMed Show Abstract
10. Louie AK, Lannon RA, Kirsch MA, et al. Venlafaxine withdrawal reactions. Am J Psychiatry. 1996;153(12):1652. PubMed Show Abstract
11. Parker G, Blennerhassett J. Withdrawal reactions associated with venlafaxine. Aust N Z J Psychiatry. 1998;32(2):291-294. PubMed doi:10.3109/00048679809062742 Show Abstract
12. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994;151(2):289. PubMed Show Abstract
13. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25(3):255-261. PubMed
14. Sabljić V, Ružić K, Rakun R. Venlafaxine withdrawal syndrome. Psychiatr Danub. 2011;23(1):117-119. PubMed Show Abstract
15. Andrade C. Antidepressant-withdrawal mania: a critical review and synthesis of the literature. J Clin Psychiatry. 2004;65(7):987-993. PubMed doi:10.4088/JCP.v65n0716Show Abstract
16. Withdrawing patients from antidepressants. Drug Ther Bull. 1999;37(7):49-52. PubMeddoi:10.1136/dtb.1999.37749 Show Abstract
17. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006;67(suppl 4):14-21. PubMed Show Abstract
18. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87. PubMed doi:10.1016/S0006-3223(98)00126-7 Show Abstract
19. Fava GA, Bernardi M, Tomba E, et al. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007;10(6):835-838. PubMed doi:10.1017/S1461145706007462 Show Abstract
20. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 1997;58(suppl 7):17-21. PubMed Show Abstract
21. Haddad PM. Do antidepressants cause dependence? Epidemiol Psichiatr Soc. 2005;14(2):58-62. PubMed Show Abstract
22. Thompson C. Discontinuation of antidepressant therapy: emerging complications and their relevance. J Clin Psychiatry. 1998;59(10):541-548. PubMed doi:10.4088/JCP.v59n1009Show Abstract
23. Antai-Otong D. Antidepressant discontinuation syndrome. Perspect Psychiatr Care. 2003;39(3):127-128. PubMed doi:10.1111/j.1744-6163.2003.00127.x Show Abstract
24. Schatzberg AF. The dynamics of sex: gender differences in psychiatric disorders. J Clin Psychiatry. 1997;58(suppl 7):3-4. PubMed Show Abstract
25. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67(suppl 4):3-7. PubMed Show Abstract
26. Wolfe RM. Antidepressant withdrawal reactions. Am Fam Physician. 1997;56(2):455-462. PubMed Show Abstract
27. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997;58(7):291-297. PubMeddoi:10.4088/JCP.v58n0702 Show Abstract
28. Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). BNF 59. London, England: BMJ Publishing Group; 2010.
29. National Institute for Health and Clinical Excellence (NICE). Depression: Treatment and Management of Depression in Adults, Including Adults With a Chronic Physical Health Problem. National Clinical Practice Guidelines Numbers 90 and 91 (update of Clinical Guideline 23). London, England: National Collaborating Centre for Mental Health; 2009.
30. Bhanji NH, Chouinard G, Kolivakis T, et al. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol. 2006;13(1):e69-e74. PubMed Show Abstract
31. Lejoyeux M, Ades J, Mourad I, et al. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs. 1996;5(4):278-292. doi:10.2165/00023210-199605040-00006
32. Berigan TR, Harazin JS. Bupropion-associated withdrawal symptoms: a case report. Prim Care Companion J Clin Psychiatry. 1999;1(2):50-51. PubMed doi:10.4088/PCC.v01n0205Show Abstract
33. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176(4):363-368. PubMed doi:10.1192/bjp.176.4.363 Show Abstract
34. Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74(3):449-456. PubMed Show Abstract
35. Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry. 2006;67(suppl 4):8-13. PubMed Show Abstract
36. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol. 2000;15(6):305-318. PubMed doi:10.1097/00004850-200015060-00001 Show Abstract
37. Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17(5):217-225. PubMed doi:10.1097/00004850-200209000-00002 Show Abstract
38. Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Serotonin Research. 1996;3(2):75-83.
39. Phillips SD. A possible paroxetine withdrawal syndrome. (letter) Am J Psychiatry. 1995;152(4):645-646. PubMed Show Abstract
40. Robinson DS. Antidepressant discontinuation syndrome. Prim Psychiatry. 2006;13(10):23-24.
41. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42(6):757-763. PubMed doi:10.1046/j.1365-2125.1996.00498.x Show Abstract
42. Baldessarini RJ, Tondo L, Ghiani C, et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167(8):934-941. PubMeddoi:10.1176/appi.ajp.2010.09060880 Show Abstract
43. Freedman R. Abrupt withdrawal of antidepressant treatment. Am J Psychiatry. 2010;167(8):886-888. PubMed doi:10.1176/appi.ajp.2010.10050783 Show Abstract
44. Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat. 2007;13(6):447-457. doi:10.1192/apt.bp.105.001966
45. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16(5):356-362. PubMed doi:10.1097/00004714-199610000-00003Show Abstract
46. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64(2):123-133. PubMed doi:10.4088/JCP.v64n0204Show Abstract
47. Dobie RA. Depression and tinnitus. Otolaryngol Clin North Am. 2003;36(2):383-388. PubMed doi:10.1016/S0030-6665(02)00168-8 Show Abstract
48. Robinson SK, Viirre ES, Bailey KA, et al. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med. 2005;67(6):981-988. PubMed doi:10.1097/01.psy.0000188479.04891.74Show Abstract
49. Zöger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26(1):32-39. PubMed doi:10.1097/01.jcp.0000195111.86650.19 Show Abstract
50. Baldo P, Doree C, Lazzarini R, et al. Antidepressants for Patients With Tinnitus (Review). The Cochrane Collaboration. London, England: John Wiley & Sons, Ltd; 2009.
51. Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. Hear Res. 2007;226(1-2):221-231. PubMed doi:10.1016/j.heares.2006.08.004 Show Abstract
52. Ahmad S. Venlafaxine and severe tinnitus. Am Fam Physician. 1995;51(8):1830. PubMed Show Abstract
53. Feder R. Tinnitus associated with amitriptyline. J Clin Psychiatry. 1990;51(2):85-86. PubMed Show Abstract
54. Pondrom MF, Brahm NC. Venlafaxine-associated tinnitus. Am J Health Syst Pharm. 2009;66(18):1606-1608, 1608. PubMed doi:10.2146/ajhp090309 Show Abstract
55. Racy J, Ward-Racy EA. Tinnitus in imipramine therapy. Am J Psychiatry. 1980;137(7):854-855. PubMed Show Abstract
56. Evans DL, Golden RN. Protriptyline and tinnitus. J Clin Psychopharmacol. 1981;1(6):404-406. PubMed doi:10.1097/00004714-198111000-00013 Show Abstract
57. Mendis D, Johnston M. An unusual case of prolonged tinnitus following low-dose amitriptyline. J Psychopharmacol. 2008;22(5):574-575. PubMeddoi:10.1177/0269881107082126 Show Abstract
58. Langguth B, Landgrebe M, Wittmann M, et al. Persistent tinnitus induced by tricyclic antidepressants. J Psychopharmacol. 2010;24(8):1273-1275. PubMeddoi:10.1177/0269881109106929 Show Abstract
59. Eggermont JJ. Tinnitus: neurobiological substrates. Drug Discov Today. 2005;10(19):1283-1290. PubMed doi:10.1016/S1359-6446(05)03542-7 Show Abstract
60. Eggermont JJ. Pathophysiology of tinnitus. Prog Brain Res.2007;166; 19-35, 543.
61. Guitton MJ, Pujol R, Puel JL. m-Chlorophenylpiperazine exacerbates perception of salicylate-induced tinnitus in rats. Eur J Neurosci. 2005;22(10):2675-2678. PubMeddoi:10.1111/j.1460-9568.2005.04436.x Show Abstract
62. Møller AR. Pathophysiology of tinnitus. Otolaryngol Clin North Am. 2003;36(2):249-266, v-vi. PubMed doi:10.1016/S0030-6665(02)00170-6 Show Abstract
63. Puel JL. Chemical synaptic transmission in the cochlea. Prog Neurobiol. 1995;47(6):449-476. PubMed doi:10.1016/0301-0082(95)00028-3 Show Abstract
64. Simpson JJ, Davies WE. A review of evidence in support of a role for 5-HT in the perception of tinnitus. Hear Res. 2000;145(1-2):1-7. PubMed doi:10.1016/S0378-5955(00)00093-9 Show Abstract
65. Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). BNF 54. London, England: BMJ Publishing Group; 2007.